A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
500 patients around the world
Available in Brazil
BeOne Medicines
1Research sites
500Patients around the world
This study is for people with
Leukemia
Chronic lymphocytic leukemia
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment.
Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2.
Measurable disease by Computer Tomography/Magnetic Resonance Imaging.
Adequate bone marrow and organ function.
Previous systemic treatment for CLL.
Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation.
Known central nervous system involvement.
History of confirmed progressive multifocal leukoencephalopathy (PML).
Uncontrolled hypertension or clinically significant cardiovascular disease.
Sites
Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa - Mãe de Deus Hospital
